IceCure Medical Ltd. Ordinary Shares 2026 Q2 Earnings Call

Eyal, please go ahead. Thank you, operator, and thank you everyone for joining us today.

The first half of 2026 marks an important inflection point for IceCure. Over the past several years, we have focused on building the clinical, regulatory, and scientific foundation for ProSense. We invested in generating clinical evidence, achieving important regulatory milestones, and educating physicians around the world. Today, we are beginning to see those investments translate into measurable commercial momentum while continuing to generate the evidence that supports future growth. We believe what makes this stage of our evolution particularly important is that our clinical and commercial strategies are no longer progressing on separate tracks. They are increasingly reinforcing one another. Growing physician adoption is generating additional real-world clinical experience that's expanding both of evidence, strengthening physician confidence, support future reimbursement initiatives, and encourage broader adoption.

As more physicians adopt ProSense, they generate additional real-world evidence, creating a self-reinforcing cycle that we believe will continue to strengthen over time. This is exactly the transition we have been working towards. During the first half of the year, revenue increased approximately 45% year-over-year to $1.8 million, driven by the growth of both ProSense systems and disposable probes. More importantly, this growth reflects increasing physician adoption and utilization of our technology across our commercial install base. One of the most meaningful indicators of commercial progress is not simply the number of systems we place, but how frequently those systems are being used. Increasing disposable probe sales suggest that physicians are incorporating ProSense into routine clinical practice and treating more patients over time. This recurring utilization gives us confidence that commercial adoption is becoming broader, deeper, and increasingly sustainable.

Following FDA clearance for early-stage, low-risk breast cancer, we continue expanding our U.S. commercial footprint, achieving approximately 70% growth in our active U.S. commercial install base. At the same time, we are strengthening our commercial organization through additional sales hires in key U.S. regions while continuing to expand our presence across select international markets. Another important example of how our clinical and commercial strategies are coming together in our FDA-approved ChoICE post-market study. I would like to emphasize an important point regarding the ChoICE Study. Unlike traditional pre-marketing clinical study, the ChoICE trial is a post-market study, it is not separate from our commercialization strategy, rather it is an extension of it. Participating clinical sites purchase disposable probe as part of the routine patient care while simultaneously contributing value real-world clinical evidence.

Some participating physicians have already transitioned from clinical investigators into active commercial users of ProSense, while additional leading institutions are joining the study and becoming end users of our technology. This means that clinical evidence generating is supporting commercial adoption, while commercial utilization is simultaneously extending the real-world evidence-supporting process. As additional sites join, we expect to achieve another important near-term milestone with the enrollment of the first patients in the ChoICE Study. We remain on track to execute against our planned objectives and look forward to providing additional update as the ChoICE Study will continue to expand. We believe that the growing body of real-world evidence generated through the ChoICE Study, together with increasing commercial adoption, will continue supporting physician confidence, future reimbursement initiatives, and a broader market adoption over time. Beyond the ChoICE Study, we continue strengthening the scientific foundation supporting ProSense.

During the first half of 2026, we reported positive five-year results from our ICESECRET kidney cancer study and presented the final data at the ECIO 2026. We also continue important recognition from the medical community through inclusion of ProSense in the American Society of Breast Surgeons' resource guide, new peer-reviewed publications in the International Journal of Surgery and PLOS ONE, and the Society of Interventional Oncology' petition requesting the inclusion of cryoablation in the National Comprehensive Cancer Network breast cancer guideline, the NCCN. Outside of the U.S., we continue making encouraging progress across several strategic international markets. In Japan, for example, we continue to engage constructively with leading physicians, medical societies, and strategic partners as we advance our long-term commercialization efforts. While regulatory process takes time, we remain encouraged by the growing level of clinical interest and engagement we continue to see.

Finally, during the second quarter of 2026, we further strengthened our balance sheet through our recent financing, ending the first half with approximately $12 million in cash and cash equivalents. This provides us with the financial flexibility to continue investing in commercial expansion, physician engagement, clinical evidence generating, and reimbursement initiatives as we execute our long-term growth strategy. When I step back and look at the first half of 2026, I don't see a series of individual milestones. I see multiple independent indicators all pointing in the same direction. Revenue growth, expanding physician adoption, increasing disposable probe utilization, continued clinical recognition, advance of the ChoICE trial, and a strengthened financial position. Individually, each of these achievements is important. Together, they tell a much bigger story.

They demonstrate that IceCure is entering a new phase of its evolution, one in which commercial execution, clinical leadership, and financial discipline are increasingly working together to build sustainable long-term shareholder value. With that, I will turn the call over to our Chief Financial Officer, Meir Peleg, who will review our financial results in greater details.